Eli Lilly and Company (LLY)
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
These are two of healthcare's biggest darlings right now, but one looks better positioned for the long run.
Should Eli Lilly Investors Worry About This Unexpected FDA Move?
Lilly has invested billions of dollars to ramp up production capacity.
Eli Lilly to invest $364M in UK trial linking obesity drug to employment
Eli Lilly, the US pharmaceutical giant behind weight-loss drugs like Zepbound and Mounjaro, has announced a strategic partnership with the UK government to tackle significant health challenges, particularly obesity.
Eli Lilly to trial use of weight loss drugs to combat unemployment in UK
The U.K. is exploring whether obesity drugs could be used to curb joblessness after signing a major investment deal with weight-loss treatment giant, Eli Lilly. The U.S. pharmaceutical company and creator of blockbuster obesity injection Zepbound announced Monday that it would commit £279 million ($364 million) to help tackle Britain's significant health challenges.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.
3 No-Brainer Growth Stocks to Buy in October
These stocks look like slam-dunk picks for growth investors.
Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
In a year and a half, Eli Lilly NYSE: LLY has roughly doubled in value. It is now the most valuable pharmaceutical company in the world.
FDA to reconsider decision barring compounded versions of Lilly weight loss drug
The U.S. Food and Drug Administration on Friday agreed to reconsider its recent decision barring drug compounders from selling their own versions of Eli Lilly's blockbuster weight loss and diabetes drugs.
Warning: This Skyrocketing Stock Has a Hidden Risk
Eli Lilly stock has jumped 200% over the past two years.
Here's Why Eli Lilly (LLY) Fell More Than Broader Market
Eli Lilly (LLY) reachead $910.69 at the closing of the latest trading day, reflecting a -0.98% change compared to its last close.
2 No-Brainer Dividend Growth Stocks to Buy Right Now
These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.
LLY Stock Rises on Congressional Budget Office Report
Eli Lilly's (LLY, Financial) stock experienced a notable movement, rising 1.71% to a price of $913.72. This surge was driven by the Congressional Budget Office (CBO) report on the potential impact if Medicare were to cover anti-obesity medications, including Eli Lilly's weight loss drug, Zepbound.
